Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer

NCT: NCT05524012 · ACTIVE_NOT_RECRUITING

NCT IDNCT05524012
StatusACTIVE_NOT_RECRUITING
Start Date2022-11-30
Completion2030-09-30
SponsorJena University Hospital (OTHER)
First posted
Last updated

Brief Summary

This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive response prediction model.

Frequently Asked Questions

What is Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer?

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer is a clinical trial registered under NCT05524012. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05524012?

The current status of NCT05524012 (Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer) is: ACTIVE_NOT_RECRUITING.

When did Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer start?

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer started on 2022-11-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑